Bellevue Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Bellevue Group’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-41,900	Closed	-$1.92M	–	140
2017 Q4	$1.92M	Sell	41,900 -1,100	-3%	-$54.9K	0.2%	79
2017 Q3	$1.93M	Hold	43,000	–	–	0.2%	82
2017 Q2	$1.28M	Buy	43,000 +6,000	+16%	+$148K	0.15%	97
2017 Q1	$821K	Hold	37,000	–	–	0.11%	106
2016 Q4	$697K	Hold	37,000	–	–	0.14%	98
2016 Q3	$1.11M	Hold	37,000	–	–	0.2%	91
2016 Q2	$1.42M	Hold	37,000	–	–	0.27%	87
2016 Q1	$1.41M	Buy	+37,000	New	+$1.29M	0.26%	88

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Bellevue Group's JUNO Position: Q1 2018 in Review

Bellevue Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 41,900 shares — an estimated $1.92M sold.

Bellevue Group first reported a position in JUNO in Q1 2016 and held it in 8 quarters. The position peaked at $1.93M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Bellevue Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Bellevue Group sold 41,900 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $1.92M.
Bellevue Group first reported a position in Juno Therapeutics, Inc. in Q1 2016 and held it in 8 quarters.
Bellevue Group's Juno Therapeutics, Inc. position peaked at $1.93M in Q3 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Bellevue Group's 13F filing for Q1 2018, filed 9 May 2018.